Bayer AG (NASDAQ:BAYRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “Bayer surpassed earnings estimates but missed revenue estimates in the second quarter of 2017. The company experienced a significant decline in sales and earnings in the Crop Science segment due to high channel inventories in Brazil. Business at Consumer Health decreased, primarily due to the difficult market environment in the U.S. Based on this, the company lowered its revenue and earnings outlook for 2017. The company is facing generic threats/competition for many of its products including the Yaz franchise (oral contraceptives). The genericization of key drugs would negatively impact revenues. Nevertheless, the company is looking forward to acquire Monsanto Company in a deal worth approximately $66 billion. With the acquisition, the combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. Yet, Bayer’s shares have outperformed the Zacks classified industry year to date.”
Separately, Berenberg Bank lowered shares of Bayer AG from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $111.00.
Shares of Bayer AG (BAYRY) opened at 129.99 on Friday. Bayer AG has a 12-month low of $91.53 and a 12-month high of $139.04.
Bayer AG (NASDAQ:BAYRY) last released its quarterly earnings data on Thursday, July 27th. The company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.87 by $0.12. Bayer AG had a net margin of 10.90% and a return on equity of 13.03%. The business had revenue of $13.41 billion for the quarter, compared to analyst estimates of $14.45 billion. Equities research analysts anticipate that Bayer AG will post $8.79 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://stocknewstimes.com/2017/08/27/zacks-investment-research-upgrades-bayer-ag-bayry-to-hold.html.
Bayer AG Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.
